Taken together, these findings show that KIN-8194 treatment results in a loss of antigen-dependent and –independent adhesion of MCL cells to FN as well as antigen-independent adhesion to stromal cells, and KIN-8194 inhibits the integrin-mediated adhesion of MCL cells which are sensitive to BTK inhibition but also of MCL cells insensitive to BTKi. The gene discussed is IBTK; the disease is mantle cell lymphoma.